170
Views
18
CrossRef citations to date
0
Altmetric
Original Article: Clinical

Successful mobilization of peripheral blood stem cells with the DHAP regimen (dexamethasone, cytarabine, cisplatinum) plus granulocyte colony-stimulating factor in patients with relapsed Hodgkin's disease

, , , , , , & show all
Pages 1017-1022 | Received 25 Jan 2005, Published online: 03 Aug 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Bei Hu, Anas Younes, Jason R. Westin, Francesco Turturro, Linda Claret, Lei Feng, Nathan Fowler, Sattva Neelapu, Jorge Romaguera, Fredrick B. Hagemeister, Maria Alma Rodriguez, Felipe Samaniego, Luis E. Fayad, Amanda R. Copeland, Loretta J. Nastoupil, Yago Nieto, Michelle A. Fanale & Yasuhiro Oki. (2018) Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leukemia & Lymphoma 59:4, pages 863-870.
Read now
Massimo Martino, Daniele Laszlo & Francesco Lanza. (2014) Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization. Expert Opinion on Biological Therapy 14:6, pages 757-772.
Read now
Ajay K. Gopal, Oliver W. Press, Andrei R. Shustov, Stephen H. Petersdorf, Ted A. Gooley, Jasmine T. Daniels, Mitchell A. Garrison, George F. Gjerset, Matthew Lonergan, Anne E. Murphy, Julie C. Smith & John M. Pagel. (2010) Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leukemia & Lymphoma 51:8, pages 1523-1529.
Read now
Yasuhiro Oki & Anas Younes. (2008) Current role of gemcitabine in the treatment of Hodgkin lymphoma. Leukemia & Lymphoma 49:5, pages 883-889.
Read now
Régis Peffault de Latour, Driss Chaoui, Jean-Henri Bourhis, Ramdane Belhocine, Sophie Park, Ollivier Legrand, Philippe Brault, Bernard Rio, F. Heshmati, Sabine Assouad & Didier Decaudin. (2007) Mobilization of peripheral blood progenitor cells after DHAP regimen with or without rituximab: A large multicenter comparative study in patients with malignant lymphoma. Leukemia & Lymphoma 48:5, pages 897-904.
Read now

Articles from other publishers (13)

Milena Todorović Balint, Nikola Lemajić, Vladimir Jurišić, Sofija Pantelić, Dejana Stanisavljević, Nada Kraguljac Kurtović & Bela Balint. (2024) An evidence-based and risk-adapted GSF versus GSF plus plerixafor mobilization strategy to obtain a sufficient CD34+ cell yield in the harvest for autologous stem cell transplants. Translational Oncology 39, pages 101811.
Crossref
Yoshikazu Ikoma, Nobuhiko Nakamura, Junichi Kitagawa, Takao Miwa, Eri Takada, Takuro Matsumoto, Yuhei Shibata, Hiroshi Nakamura, Nobuhiro Kanemura, Senji Kasahara, Takeshi Hara, Michio Sawada, Hisashi Tsurumi & Masahito Shimizu. (2023) A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non‐Hodgkin lymphoma. Hematological Oncology.
Crossref
Katharina Kriegsmann & Patrick Wuchter. 2019. Stem Cell Mobilization. Stem Cell Mobilization 41 58 .
Katharina Kriegsmann, Anita Schmitt, Mark Kriegsmann, Thomas Bruckner, Adamma Anyanwu, Mathias Witzens-Harig, Carsten Müller-Tidow, Stefan Klein & Patrick Wuchter. (2018) Orchestration of Chemomobilization and G-CSF Administration for Successful Hematopoietic Stem Cell Collection. Biology of Blood and Marrow Transplantation 24:6, pages 1281-1288.
Crossref
Ilhami Berber, Mehmet Ali Erkurt, Irfan Kuku, Emin Kaya, Harika Gozukara Bag, Ilknur Nizam, Mustafa Koroglu & Mustafa Ozgul. (2016) DHAP plus filgrastim as an effective peripheral stem cell mobilization regimen for autologous stem-cell transplantation in patients with relapsed/refractory lymphoma: A single center experience. Transfusion and Apheresis Science 54:1, pages 48-52.
Crossref
Sebastian Giebel, Maria Sadus-Wojciechowska, Kazimierz Halaburda, Joanna Drozd-Sokolowska, Agnieszka Wierzbowska, Jacek Najda, Wlodzimierz Mendrek, Malgorzata Sobczyk-Kruszelnicka, Mateusz Nowicki, Jerzy Holowiecki & Tomasz Czerw. (2015) Increased efficacy of intermediate-dose cytarabine + G-CSF compared to DHAP + G-CSF for stem cell mobilization in patients with lymphoma: an analysis by the polish lymphoma research group. Annals of Hematology 95:2, pages 263-269.
Crossref
Thomas C. Shea & John F. DiPersio. 2015. Thomas’ Hematopoietic Cell Transplantation. Thomas’ Hematopoietic Cell Transplantation 452 462 .
L. C. Fox, S. J. Ragg, R. M. Lowenthal, E. M. Tegg & A. M. Johnston. (2014) Use of ‘rainy day’ autologous haemopoietic stem cells: a single-institution experience over 10 years. Internal Medicine Journal 44:9, pages 897-902.
Crossref
Andreas JostingHorst MüllerPeter BorchmannJoke W. BaarsBernd MetznerHartmut DöhnerIgor AurerLenka SmardovaThomas FischerDietger NiederwieserKerstin Schäfer-EckartNorbert SchmitzAnna SuredaJan GlossmannVolker DiehlDaphne DeJongMartin-Leo HansmannJohn RaemaekersAndreas Engert. (2010) Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma. Journal of Clinical Oncology 28:34, pages 5074-5080.
Crossref
Matteo Pelosini, Daniele Focosi, Fazzi Rita, Sara Galimberti, Francesco Caracciolo, Edoardo Benedetti, Federico Papineschi & Mario Petrini. (2007) Progressive multifocal leukoencephalopathy: report of three cases in HIV-negative hematological patients and review of literature. Annals of Hematology 87:5, pages 405-412.
Crossref
Esa Jantunen & Taru Kuittinen. (2008) Blood stem cell mobilization and collection in patients with lymphoproliferative diseases: practical issues. European Journal of Haematology 80:4, pages 287-295.
Crossref
M Magagnoli, M Spina, M Balzarotti, I Timofeeva, L Isa, M Michieli, R Capizzuto, E Morenghi, L Castagna, U Tirelli & A Santoro. (2007) IGEV regimen and a fixed dose of lenograstim: an effective mobilization regimen in pretreated Hodgkin's lymphoma patients. Bone Marrow Transplantation 40:11, pages 1019-1025.
Crossref
. (2005) Current Awareness in Hematological Oncology. Hematological Oncology 23:3-4, pages 136-143.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.